185 related articles for article (PubMed ID: 26386624)
1. Lysergic Acid Diethylamide and Psilocybin Revisited.
Geyer MA
Biol Psychiatry; 2015 Oct; 78(8):516-8. PubMed ID: 26386624
[No Abstract] [Full Text] [Related]
2. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
Schmid Y; Enzler F; Gasser P; Grouzmann E; Preller KH; Vollenweider FX; Brenneisen R; Müller F; Borgwardt S; Liechti ME
Biol Psychiatry; 2015 Oct; 78(8):544-53. PubMed ID: 25575620
[TBL] [Abstract][Full Text] [Related]
3. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
[TBL] [Abstract][Full Text] [Related]
4. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.
Schartner MM; Carhart-Harris RL; Barrett AB; Seth AK; Muthukumaraswamy SD
Sci Rep; 2017 Apr; 7():46421. PubMed ID: 28422113
[TBL] [Abstract][Full Text] [Related]
5. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME
Clin Pharmacokinet; 2017 Oct; 56(10):1219-1230. PubMed ID: 28197931
[TBL] [Abstract][Full Text] [Related]
7. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR
J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231
[TBL] [Abstract][Full Text] [Related]
8. High hopes.
Kupferschmidt K
Science; 2014 Jul; 345(6192):18-23. PubMed ID: 24994630
[No Abstract] [Full Text] [Related]
9. Psychedelic use and intimate partner violence: The role of emotion regulation.
Thiessen MS; Walsh Z; Bird BM; Lafrance A
J Psychopharmacol; 2018 Jul; 32(7):749-755. PubMed ID: 29807492
[TBL] [Abstract][Full Text] [Related]
10. Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects.
Abramson HA; Rolo A
J Asthma Res; 1965 Sep; 3(1):81-96. PubMed ID: 5318626
[No Abstract] [Full Text] [Related]
11. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.
Garcia-Romeu A; Richards WA
Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of isolation-induced attack behavior of mice by drugs.
Uyeno ET
J Pharm Sci; 1966 Feb; 55(2):215-6. PubMed ID: 5923276
[No Abstract] [Full Text] [Related]
13. LYSERGIC ACID DIETHYLAMIDE (LSD-25). 34. COMPARISON WITH EFFECT OF PSILOCYBIN ON THE SIAMESE FIGHTING FISH.
ABRAMSON HA; GETTNER HH; ROLO A; DEAN G
J Psychol; 1963 Oct; 56():363-74. PubMed ID: 14051981
[No Abstract] [Full Text] [Related]
14. Psychedelic-Assisted Group Therapy: A Systematic Review.
Trope A; Anderson BT; Hooker AR; Glick G; Stauffer C; Woolley JD
J Psychoactive Drugs; 2019; 51(2):174-188. PubMed ID: 30950777
[TBL] [Abstract][Full Text] [Related]
15. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
[TBL] [Abstract][Full Text] [Related]
16. Psychedelic microdosing benefits and challenges: an empirical codebook.
Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E
Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862
[TBL] [Abstract][Full Text] [Related]
17. EFFECT OF MESCALINE, LYSERGIC ACID DIETHYLAMIDE AND PSILOCYBIN ON COLOR PERCEPTION.
HARTMAN AM; HOLLISTER LE
Psychopharmacologia; 1963 Aug; 4():441-51. PubMed ID: 14048565
[No Abstract] [Full Text] [Related]
18. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
Ross S
Int Rev Psychiatry; 2018 Aug; 30(4):317-330. PubMed ID: 30102082
[TBL] [Abstract][Full Text] [Related]
19. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.
Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H
Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617
[TBL] [Abstract][Full Text] [Related]
20. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Lea T; Amada N; Jungaberle H; Schecke H; Klein M
Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
